PR Newswire UK (press release) All patients received oral dexamethasone on day 1. The primary efficacy endpoint was complete response during the delayed phase. About the Pivotal Phase II Study. The Phase II study, which was designed to determine the proper dose of netupitant to ...
Genetic Engineering News Further, the firm will also present Phase II safety and efficacy results on elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma, along with partner AbbVie. And Gilead Sciences also announced results from a ... and more »
FiercePharma Release | Analyst Report; New data on Onyx Pharmaceuticals' ($ONXX) multiple myeloma drug Kyprolis showed its effectiveness in various combination therapies...
MarketWatch (press release) Interviewed thought leaders are optimistic that the CRd regimen-- carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone --will show advantages over sales-leading ... and more »
7thSpace Interactive (press release) Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe ...
